FDA To Reveal RFID Test Results at Fifth RFID Academic Convocation

Manufacturing News, Source : The Manufacturer US
Zone : IT in manufacturing
Published : 05 Mar 2007 19:30

March 5, 2007 — The Food and Drug Administration (FDA) will reveal methods and results of tests completed to determine the effects of RFID readers on implanted cardiac pacemakers and defibrillators during the fifth RFID Academic Convocation, being held April 30 in Orlando, Florida, in conjunction with RFID Journal LIVE! 2007, the fifth annual conference and exhibition produced by RFID Journal.

Seth Seidman, an electrical engineer in the FDA’s Division of Physics, Office of Science and Engineering Labs, Center for Devices of Radiological Health, will present a paper he co-authored with Paul Ruggera, Randall Brockman, Brian Lewis and Mitchell Shein on “Electromagnetic Compatibility of Pacemakers and Implantable Cardiac Defibrillators Exposed to RFID Readers”.

“This session will be of interest for anyone in the medical device community who is interested in test methodologies for evaluating the impact of HF and UHF RFID systems,” says Stephen Miles, co-chair of the RFID Academic Convocation and a research engineer at the MIT Auto-ID Lab. “The results are being presented for the first time and will be of great interest to those looking to leverage the benefits RFID offers in the health care and life sciences fields.”

The HLS track within the convocation will also feature presentations by Carolyn Walton, vice president of Wal-Mart, on the Health Care Supply Chain; Ron Bone, senior vice president of distribution planning at McKesson, and Mike Rose, senior vice president, strategy at Johnson and Johnson, who will address standards progress and research issues during the health care and life sciences track. Both are members of the EPCglobal Healthcare Life Sciences Business Action Group.

“We invite everyone from the health care field to provide input as to how researchers can best serve HLS industry stakeholders who are working to meet objectives set forth in EPA guidelines and e-pedigree laws in California and other states,” says Miles.

The requirements were first articulated in the FDA Prescription Drug Marketing Act of 1987 (PDMA), which was enacted to ensure that drug products purchased by consumers are safe and effective and to avoid the unacceptable risk to American consumers from counterfeit, adulterated, misbranded, subpotent, or expired drugs.

Comments on this story

click here to add a comment